Source disclosure: March 06, 2026, 16:00 JST
Published by Pulse News Wire: March 06, 2026, 16:34 JST
3-D Matrix,Ltd. [7777.T]
TOKYO, Mar 06 (Pulse News Wire) – 3-D Matrix,ltd. (7777.T) filed a CE mark change application with European regulatory authorities to expand the uses of its hemostatic agent PuraStat for mucosal wound healing applications.
This marks the company's first CE mark modification request aimed at adding indications for mucosal tissue repair, particularly targeting gastrointestinal and ENT areas. Successful approval could differentiate PuraStat from competitors by enabling its use beyond bleeding control to treat non-hemorrhagic conditions such as post-resection sites and ulcers. Additionally, the application seeks to address conditions like radiation proctitis and vascular lesions, potentially broadening clinical utility across digestive tract treatments.
In parallel, the company also applied for CE mark changes to reduce post-operative adhesions and pain in ENT procedures. Approval would position PuraStat as a differentiated product offering clinical value in the ENT market. With these expanded functionalities, 3-D Matrix aims to establish PuraStat as a multifunctional device capable of hemostasis, healing, adhesion prevention, and pain relief, accelerating its adoption in the European market.
As of now, there is no expected impact on the company’s full-year earnings forecast.
AI-translated content. 🟢 Confidence: High See terms • Original filing